Results 21 to 30 of about 188,239 (260)

Do clinical trials conducted in India match its healthcare needs? An audit of the Clinical Trials Registry of India

open access: yesPerspectives in Clinical Research, 2017
Background: India continues to contribute disproportionately to the global burden of disease and public health research output from India is also known to be not commensurate with her healthcare needs.
Mansi Chaturvedi   +2 more
doaj   +1 more source

Estimating and validating disability-adjusted life years at the global level: a methodological framework for cancer

open access: yesBMC Medical Research Methodology, 2012
Background Disability-adjusted life years (DALYs) link data on disease occurrence to health outcomes, and they are a useful aid in establishing country-specific agendas regarding cancer control.
Soerjomataram Isabelle   +6 more
doaj   +1 more source

Estimation of disability weight for paragonimiasis: a systematic analysis

open access: yesInfectious Diseases of Poverty, 2018
Background Paragonimiasis, caused by helminths of the genus Paragonimus spp., is a neglected tropical disease. Human suffering from paragonimiasis is often misunderstood and its quantification by the disability weight of the disability-adjusted life ...
Yun Feng   +3 more
doaj   +1 more source

Burden of cancers in India - estimates of cancer crude incidence, YLLs, YLDs and DALYs for 2021 and 2025 based on National Cancer Registry Program

open access: yesBMC Cancer, 2022
Background Cancer is the major cause of morbidity and mortality worldwide. The cancer burden varies within the regions of India posing great challenges in its prevention and control.
Vaitheeswaran Kulothungan   +9 more
doaj   +1 more source

Global, regional, and national trends in mesothelioma burden from 1990 to 2019 and the predictions for the next two decades

open access: yesSSM: Population Health, 2023
Objectives: We aimed to analyze the secular trends in mesothelioma burden, the effect of age, period, and birth cohort, and project the global burden over time. Material and methods: Based on the mesothelioma incidence, mortality, and Disability-Adjusted
Wenmin Zhu   +4 more
doaj   +1 more source

Time‐resolved dynamic disability adjusted life‐years estimation

open access: yesIndoor Air, 2022
The quantification of how healthy the indoor air is, is a complex issue comprising of a large number of contaminants of various sources. The health implication of exposure to each of the contaminant deemed of importance can be expressed using Disability Adjusted Life Years (DALYs).
Klaas De Jonge, Jelle Laverge
openaire   +3 more sources

Cross-national agreement on disability weights: the European Disability Weights Project

open access: yesPopulation Health Metrics, 2003
Background Disability weights represent the relative severity of disease stages to be incorporated in summary measures of population health. The level of agreement on disability weights in Western European countries was investigated with different ...
Burström Kristina   +3 more
doaj   +1 more source

The global burden of neglected zoonotic diseases: Current state of evidence

open access: yesOne Health, 2023
The majority of emerging infectious diseases are zoonoses, most of which are classified as “neglected”. By affecting both humans and animals, zoonoses pose a dual burden.
Carlotta Di Bari   +12 more
doaj   +1 more source

3. Calculating disability adjusted life years [PDF]

open access: yesNew South Wales Public Health Bulletin Supplementary Series, 1900
This chapter introduces the formula used for calculating a DALY and its components. The calculations and formulae are not essential to assessing the effort and time involved in conducting the study, as most of the effort is expended in the data collation and processing stage before the formulae are applied.
Doug Lincoln, David Muscatello
openaire   +1 more source

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. ABSTRACT Objective Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.
Ralf Gold   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy